-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。FSLRは、2026年第1四半期に過去最高の売上高10億4,000万ドル（前年同期比24%増、市場予想とほぼ一致）を達成し、モジュール販売量も過去最高の3.8GWを記録しました。これにより、粗利益率は46.5%（570bps増）に拡大し、希薄化後1株当たり利益（EPS）は3.22ドルとなり、市場予想の2.83ドルを上回りました。調整後EBITDAは5億1,980万ドル（前年同期比37%増、市場予想を12%上回る）に達し、利益率は49.8%（500bps増）に拡大し、高い営業レバレッジ効果を示しました。受注残高は前期の50.1GWから47.9GWに減少しており、売上高が新規受注を上回るペースで推移していることから、この傾向は懸念材料であり、今後の動向を注視する必要があります。経営陣は、第2四半期のモジュール販売量を3.4～4.0GW、セクション45X税額控除額を3億3,000万～4億ドルと予測しています。開発業者が2026年7月4日の税額控除資格期限に間に合わせようと急ぐため、商業用太陽光発電プロジェクトの活動は年中にかけて加速し、第2四半期と第3四半期の受注に転換点をもたらす可能性があると予想されます。セクション45X税額控除は通年で21億5,000万ドルと予測されており、FSLRの統合製造アプローチは、IRA支援を活用する上で有利な立場にあります。
Related Articles
Asia
Telix Says Marketing Authorization Application for Glioma Imaging Candidate Accepted for Review in Europe; Shares Up 3%
Telix Pharmaceuticals (ASX:TLX) said Friday its marketing authorization application filed in Europe for TLX101-Px, its glioma imaging candidate, has been validated and accepted for review, moving into a 210-day active assessment phase.In a statement, the company said it is seeking a broad clinical label, reflective of current clinical practice guidelines, with national marketing authorizations expected to follow shortly after a positive outcome at day 210.The company said it aims to expand patient access to advanced imaging that can distinguish progressive or recurrent glioma from treatment-related changes in both adults and children, with potential for additional future indications.TLX101-Px is also being developed as a patient selection and response assessment tool for Telix's glioblastoma therapy candidate TLX101-Tx, which has been granted orphan drug designation in Europe and the US, per the statement.The phase 3 IPAX-BrIGHT trial of TLX101-Tx in patients with recurrent glioblastoma has started patient dosing internationally and is launching in multiple European countries, the company said.Telix Pharmaceuticals' shares were up 3% in recent Friday trade.
$ASX:TLX
Asia
Zozo's Profit Climbs 6% in Fiscal Year 2025
Zozo's (TYO:3092) profit attributable to owners of the parent rose 5.7% to 47.93 billion yen for the fiscal year 2025 from 45.35 billion yen a year earlier.The shopping mall operator's basic earnings per share increased to 54.11 yen from 50.90 yen a year ago, according to a Tokyo bourse filing on Thursday.Net sales climbed 7.2% to 228.37 billion yen for the full year ended March 31 from 213.13 billion yen in the prior year.The company declared a year-end dividend of 20 yen per share, payable from June 11.For the fiscal year 2026, the company expects attributable profit of 49.7 billion yen, EPS of 56.20 yen, and net sales of 241.9 billion yen.Zozo plans to pay interim and year-end dividends of 20 yen per share each for the year, which is higher than the amount in the year-ago period.
$TYO:3092
Asia
EML Payments Says Regulators Extend Date for Implementation of Required Guarantee Structure
EML Payments (ASX:EML) said the Australian Prudential Regulation Authority (APRA) and Reserve Bank of Australia (RBA) agreed to extend the date for implementation of the required authorized deposit-taking institution guarantee structure, subject to EML Payment Solutions showing "satisfactory progress" towards obtaining the guarantee via periodic reporting, according to a Friday Australian bourse filing.EML Payment Solutions is engaging with several domestic and international financial institutions, as well as legal advisors and trustee service providers, to design the required guarantee structure.The regulators had earlier said that they require the firm to obtain a guarantee from an authorized deposit-taking institution in respect of stored value liabilities for certain EML Payment Solutions programs by Thursday.
$ASX:EML